Transcript
Dr. Neal Bhatia: There was a multicenter real-world study looking at swapping from a TNF inhibitor to an IL-17 inhibitor, then after cycling to another TNF inhibitor. At about 60 months, the retention was about 50%, maybe a little bit more, as compared to 28% in the TNF group. But again, in the meta-analysis they looked at over time, they didn't find much of a significant difference in their retention. How would you interpret some of that study data? What does that mean to the dermatologist in practice?
Dr. Lourdes Perez-Chada: So we are referring to this meta-analysis that has five observational studies about cycling and swapping, right?
Dr. Neal Bhatia: Right.
Dr. Lourdes Perez-Chada: Yeah. So that meta-analysis, I'm familiar with it. One thing to consider about that one is that it has very high heterogeneity. These are five good observational studies, but when integrating all these data together, we do have to take into account the heterogeneity among the studies. The overarching message of that study is that following TNF failure, cycling and swapping strategies were comparable in terms of retention and safety. So this is ultimately suggesting that the treatment choice will be guided more by the clinical characteristics and preferences of the patients rather than the overall effectiveness.
Dr. Neal Bhatia: Yeah, because one would think you're risking some pretty strong, maybe potentially irreversible joint damage if that isn't being treated thoroughly, correct? Or if we're sitting on treatment and not moving forward, how does that possibility of irreversible joint damage affect our ability to just stay settled on a partial response?
Dr. Lourdes Perez-Chada: Yeah, so irreversible joint damage is a big problem and definitely affects the function of patients. It also affects patients in terms of these definitions, for example, of minimal disease activity, which is one of the targets that you have under the concept of treat-to-target in psoriatic arthritis. One of the ways in which you can define that a patient is at target is using this metric of MDA, minimal disease activity. Under this outcome, MDA, you need to fulfill five of seven criteria to be considered at minimal disease activity. But there is a slight problem with that, which is that a patient who has damage may still, even though the patient does not have active inflammation at that moment, have difficulties achieving that target of minimal disease activity because of the presence of damage.
So that becomes very important to note for clinical interpretation and also for trial interpretation and registry data interpretation.
Damage might always lead to problems with functional scores and pain scores that might be wrongly interpreted as a patient having active inflammation that requires us to swap or cycle the therapy. But even by cycling or swapping therapies, we might not be improving those scores. Does that make sense?
Dr. Neal Bhatia: Yeah.
Dr. Lourdes Perez-Chada: Because the patient has damage, and that will not be modified by a different agent. We just have to maybe focus on a different type of therapy to improve that aspect of the patient.
Dr. Neal Bhatia: Yeah. That actually brings us to the next topic of what is missing in our treatment landscape. Are there emerging therapies that we should be paying closer attention to, or should we just focus more on disease awareness? And should dermatologists especially be taking more responsibility for making that diagnosis early? What part of that whole equation should we be focusing on?
Dr. Lourdes Perez-Chada: Well, definitely, I think that the key thing for us to focus on as dermatologists is to be mindful of the presence of psoriatic arthritis, screen patients to the best of our ability with the resources we have, which is at least knowing the questions that you should ask in the clinic. Ask your patients about joint pain, stiffness, and swelling, and refer them to a rheumatologist if you believe that the patient is at a higher risk.
Second, I think if you suspect psoriatic arthritis in your patient and you don't have the network or resources to refer the patient promptly to rheumatology, select an agent from those that are already available and approved by the FDA that you know can treat psoriatic arthritis, right?
